Cyclo Therapeutics Inc (CYTH) |
|
7.84 -0.4 (-4.85%)
|
03-05 08:43 |
|
Open: |
8.2 |
Pre. Close: |
8.24 |
|
High:
|
8.49 |
Low:
|
7.6 |
|
Volume:
|
276,564 |
Market Cap:
|
36M |
|
|
|
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
8.508 - 8.559 |
8.559 - 8.597 |
|
Low:
|
7.488 - 7.55 |
7.55 - 7.596 |
|
Close:
|
7.757 - 7.85 |
7.85 - 7.92 |
|
Technical analysis |
as of: 2021-03-05 8:09:14 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 15.45 One year: 20.73 |
| Support: |
Support1: 5.92 Support2: 4.93 |
| Resistance: |
Resistance1: 13.23 Resistance2: 17.75 |
| Pivot: |
9.00  |
| Moving Average: |
MA(5): 8.28 MA(20): 9.72
MA(100): 8.40 MA(250): 12.79 |
| MACD: |
MACD(12,26): 0.10 Signal(9): 0.42 |
| Stochastic oscillator: |
%K(14,3): 11.84 %D(3): 11.38  |
| RSI: |
RSI(14): 46.46 |
| 52-week: |
High: 30.00 Low: 3.00 Change(%): -44.0 |
| Average Vol(K): |
3-Month: 160972 10-Days: 24094 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.CYTH has closed above bottom band by 20.1%. Bollinger Bands are 29.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 04 Mar 2021
Cyclo Therapeutics (CYTH) Reports Complete Patient Visit in Phase 1/2 Trial Evaluating Trappsol Cyclo for Treatment of Niemann-Pick Disease Type C - StreetInsider.com
Thu, 04 Mar 2021
Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C - Business Wire
Tue, 02 Mar 2021
Cyclo Therapeutics (CYTH) Receives a Buy from Maxim Group - Smarter Analyst
Mon, 01 Mar 2021
Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer - Business Wire
Mon, 22 Feb 2021
Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families - Valdosta Daily Times
Tue, 16 Feb 2021
Cyclo Therapeutics: A Potential Gem In The Fight Against Alzheimer's Disease - Seeking Alpha
|
Financial Analysis |
| Growth |
NA |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
NA |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
NA |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
NA |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Neutral |
Discounted cash flow: |
Neutral |
| Return on Assets: |
Neutral |
Price to Earnings: |
Neutral |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: |
| Industry: |
| Shares Out. (M) |
5 |
| Shares Float (M) |
1 |
|
% Held by Insiders
|
10.24 |
|
% Held by Institutions
|
0.06 |
|
Shares Short (K)
|
126 |
|
Shares Short P. Month (K)
|
5 |
Stock Financials |
|
EPS
|
|
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
|
|
Profit Margin
|
|
|
Operating Margin
|
-905.22 |
|
Return on Assets (ttm)
|
-111.5 |
|
Return on Equity (ttm)
|
-601.4 |
|
Qtrly Rev. Growth
|
-22.2 |
|
Gross Profit (p.s.)
|
0.168 |
|
Sales Per Share
|
0.216 |
|
EBITDA (p.s.)
|
-1.950 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-8 |
|
Levered Free Cash Flow (M)
|
-4 |
Stock Valuations |
|
PE Ratio
|
|
|
PEG Ratio
|
|
|
Price to Book value
|
|
|
Price to Sales
|
36.37 |
|
Price to Cash Flow
|
-4.65 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
